Can I Take Resveratrol with Vardenafil (Levitra/Staxyn)?

Vardenafil is an FDA-approved phosphodiesterase type 5 (PDE5) inhibitor sold as Levitra (film-coated tablet) and Staxyn (orally disintegrating tablet), used to treat erectile dysfunction [1]. Resveratrol is a stilbene polyphenol found in red grape skins and sold in the United States as an unregulated dietary supplement, typically in doses of 100 mg to 1,500 mg. It has no FDA-approved medical indication.

The core finding, stated plainly: vardenafil depends on hepatic CYP3A4 for the majority of its clearance, and in vitro studies have reported that trans-resveratrol can inhibit CYP3A4 at micromolar concentrations; whether typical oral supplement doses reach inhibitory concentrations at the liver is unresolved because resveratrol has very low systemic bioavailability [7]. No human trial has measured vardenafil levels or blood pressure when the two are co-administered, so any specific numeric estimate of the combined effect in a real patient should be treated as unverified. The practical response for most healthy adults is caution and monitoring rather than avoidance, but people on antihypertensives, alpha-blockers, or with hepatic impairment face a materially different risk profile and should not self-manage this combination.

Why this combination raises a question

PDE5 inhibitors like vardenafil relax vascular smooth muscle and lower blood pressure as part of their mechanism [1]. Resveratrol has been studied for cardiovascular effects including nitric-oxide-pathway enhancement and mild enzyme inhibition [2]. The overlap that matters clinically is twofold: a possible pharmacokinetic interaction at the liver (CYP3A4) and a pharmacodynamic overlap (both can lower blood pressure). Neither mechanism has been tested with the two agents given together in people; each is inferred from separate lines of evidence.

What the FDA label establishes about vardenafil and CYP3A4

Vardenafil's prescribing information is reported to describe substantial increases in vardenafil exposure when co-administered with potent CYP3A4 inhibitors such as ketoconazole and ritonavir, and to instruct dose limits or avoidance in that setting. This is the primary, FDA-sourced evidence anchor for the general principle that CYP3A4 inhibition raises vardenafil blood levels. The label does not mention resveratrol, and the magnitude of any resveratrol effect has not been established through a comparable interaction study. Readers who want the exact fold-change figures for ketoconazole or ritonavir should confirm them against the current label text directly rather than relying on a secondhand restatement.

Resveratrol is not comparable in potency to ketoconazole or ritonavir. It is more accurately described, based on in vitro data, as a weak-to-moderate CYP3A4 inhibitor, similar in category (though not necessarily in magnitude) to a mild inhibitor rather than a potent one.

The pharmacokinetic question: does oral resveratrol reach an inhibitory concentration?

In vitro enzyme studies have reported that trans-resveratrol inhibited CYP3A4 activity, with IC50 values described in the low single-digit to mid double-digit micromolar range depending on the probe substrate used. A pharmacokinetic study in healthy volunteers given a single 500 mg oral dose of trans-resveratrol measured peak plasma concentrations in the sub-micromolar range, below the in vitro inhibitory concentrations found in microsome studies [7]. That gap is the central uncertainty in this interaction: systemic plasma levels after typical supplement dosing appear lower than the concentrations that produced enzyme inhibition in vitro, but portal vein concentrations delivered to the liver before first-pass metabolism could be higher than systemic levels. Whether that first-pass exposure reaches a clinically meaningful inhibitory threshold at commonly sold doses (250 mg to 1,500 mg) has not been directly measured and should be considered unresolved rather than confirmed either way.

This is why a single 100 mg resveratrol capsule and a 1,000 mg dose are not equivalent from a risk standpoint, even though neither has been tested directly with vardenafil.

The pharmacodynamic question: additive blood pressure lowering

Vardenafil produces a measurable, transient drop in blood pressure around peak plasma concentration, an effect described in its clinical trial data. Separately, a meta-analysis of randomized controlled trials found that resveratrol at doses of 150 mg or higher lowered systolic blood pressure in people with elevated baseline readings, with a much smaller effect in normotensive participants [8]. These are two independently documented effects; no trial has measured what happens when both are present in the same person at the same time. The plausible concern, not a demonstrated one, is that a person who is hypertensive, taking an antihypertensive, and using both vardenafil and resveratrol on the same day could experience a larger blood pressure drop than either substance alone would predict.

Evidence-status assessment: resveratrol and vardenafil

What a pharmacist or prescriber should verify before green-lighting this combination: the patient's current blood pressure and antihypertensive regimen, hepatic function status, the vardenafil dose being considered, the resveratrol dose and formulation, and whether the patient is also using grapefruit juice, alpha-blockers, or other CYP3A4-modulating substances on the same day.

Practical guidance if both are used

No professional guideline specifically addresses resveratrol and vardenafil together. The following reflects pharmacologic reasoning drawn from general CYP3A4 principles, not a study of this exact pair.

Timing. Vardenafil reaches peak plasma concentration around 60 minutes on an empty stomach (longer with a high-fat meal) and has an elimination half-life of roughly 4 to 5 hours. Separating resveratrol and vardenafil doses by at least 4 hours reduces the window of simultaneous hepatic competition for CYP3A4, though this spacing has not itself been validated in a trial.

Dose. Starting at the lowest approved vardenafil dose (5 mg) when introducing resveratrol mirrors the label's own precautionary approach for moderate CYP3A4 inhibitors like erythromycin, even though resveratrol has not been formally classified at that potency.

Avoid stacking CYP3A4 burdens. Grapefruit juice also inhibits CYP3A4, through a different (irreversible, intestinal) mechanism than resveratrol's reversible hepatic inhibition. Combining grapefruit juice, resveratrol, and vardenafil on the same day compounds enzyme inhibition from two directions; reducing to one CYP3A4-active substance per dosing window is a simpler and more conservative approach.

Who should not manage this combination without a prescriber

• Men taking alpha-blockers (tamsulosin, doxazosin), where vardenafil already carries a labeled hypotension caution independent of any supplement
• Men with hepatic impairment, where vardenafil clearance is already reduced according to pharmacokinetic data in that population
• Men on antihypertensive medication, where the additive blood-pressure question is least studied and most consequential
• Anyone taking vardenafil 20 mg, the maximum approved dose, where the margin for an unexpected increase in exposure is narrowest

For men without these risk factors, normal baseline blood pressure, and no other CYP3A4-active substances, the risk is lower but not zero, and disclosure to a prescriber or pharmacist remains the safer path rather than self-titrating.

Monitoring if you choose to combine them

Check seated blood pressure before first combined use and again 60 to 90 minutes after taking vardenafil. A systolic reading below 90 mmHg, or a drop of more than 20 mmHg from baseline, is a reason to stop one of the two agents and contact a prescriber rather than wait it out [3]. Watch for worsening of vardenafil's known dose-related side effects, including headache, flushing, nasal congestion, and dyspepsia, as reported in its clinical trial data; a noticeable increase after adding resveratrol is a reasonable trigger to reassess timing or dose with a clinician, not to stop monitoring on your own.

Seek urgent care for fainting, chest pain, sudden vision changes, or an erection lasting more than 4 hours, regardless of supplement use.

What the evidence does not yet tell us

No randomized controlled trial has tested resveratrol combined with vardenafil in humans. Everything above is extrapolated from three separate bodies of evidence: vardenafil's FDA-reviewed pharmacology, in vitro CYP3A4 inhibition data for resveratrol, and each compound's independently studied blood pressure effects. A narrative review on resveratrol's broader pharmacology noted that the clinical significance of its CYP3A4 inhibition is difficult to pin down given the compound's low systemic bioavailability and rapid metabolic conjugation [13]. That uncertainty applies directly here: the interaction is pharmacologically plausible, but its real-world magnitude in a person taking both vardenafil and resveratrol has not been measured. A quoted claim describing a specific guideline as naming resveratrol by name could not be independently confirmed in the source material used for this draft and has been removed rather than restated; readers should not assume any specific medical society has issued resveratrol-specific guidance until that is verified against the primary document.